

## UNITED STATES PATENT AND TRADEMARK OFFICE



DATE MAILED: 10/22/2002 14

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/774,434 01/30/2001		Y. Tom Tang	21272-029CIP2G	3487
7	590 10/22/2002			
Ivor R. Elrifi Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.			EXAMINER	
			SOUAYA, JI	YA, JEHANNE E
One Financial Center Boston, MA 02111			ART UNIT	PAPER NUMBER
			1634	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

Application No.

Applicant(s,

09/774,434

Tang et al

Examiner

Jehanne Souaya

Art Unit 1634



The MAILING DATE of this communication appears	on the cover sheet with the correspondence address				
Period for Reply					
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.					
- Extensions of time may be available under the provisions of 37 CFR 1.136 (a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.					
<ul> <li>If the period for reply specified above is less than thirty (30) days, a reply within the lif NO period for reply is specified above, the maximum statutory period will apply a Failure to reply within the set or extended period for reply will, by statute, cause the Any reply received by the Office later than three months after the mailing date of the earned patent term adjustment. See 37 CFR 1.704(b).</li> </ul>	and will expire SIX (6) MONTHS from the mailing date of this communication.  The application to become ABANDONED (35 U.S.C. § 133).				
Status					
1) Responsive to communication(s) filed on Aug 5, 20	002 .				
2a) ☐ This action is <b>FINAL</b> . 2b) ☐ This act	ion is non-final.				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.					
Disposition of Claims					
4) 💢 Claim(s) <u>1-8 and 21-25</u>	is/are pending in the application.				
4a) Of the above, claim(s)	is/are withdrawn from consideration.				
5) Claim(s)	is/are allowed.				
6) Claim(s)	is/are rejected.				
7)	is/are objected to.				
8) 💢 Claims <u>1-8 and 21-25</u>	are subject to restriction and/or election requirement.				
Application Papers					
9) The specification is objected to by the Examiner.					
10) ☐ The drawing(s) filed on is/are a) ☐ accepted or b) ☐ objected to by the Examiner.					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).					
11) The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Exami	ner.				
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) All b) Some* c) None of:					
1. $\square$ Certified copies of the priority documents hav	e been received.				
2. $\square$ Certified copies of the priority documents hav	e been received in Application No				
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).					
*See the attached detailed Office action for a list of the certified copies not received.					
14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).					
a) The translation of the foreign language provisional application has been received.  15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
15) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.  Attachment(s)					
1) Notice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)				
3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)					

## **DETAILED ACTION**

Applicants election of SEQ ID NO 6 is noted. Applicants also indicate that the invention of Group I, claims 1-8 and 21-25 has been elected, however, the previous restriction requirement set forth claims 1-8 in Group I and claims 21-25 in Group VIII. A new restriction requirement is set forth below with regard to the claims pending, claims 1-8 and 21-25, it is noted however, that the new restriction requirement places claim 21 in Group I.

## Election/Restriction

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
  - I. Claims 1-8 and 21, drawn to a polynucleotide, vectors and host cells comprising such, classified in class 536, subclass 23.1, class 435, subclass 320.1, and class 435, subclass 252.1, respectively.
  - II. Claims 22-25, drawn to a nucleic acid array, classified in class 435, subclass 287.2.
- 2. The inventions are distinct, each from the other because of the following reasons:

  The inventions of groups I and II are related as combination and subcombination. Inventions in this relationship are distinct if it can be shown that (1) the combination as claimed does not require the particulars of the subcombination as claimed for patentability, and (2) that the subcombination has utility by itself or in other combinations (MPEP § 806.05(c)). In the instant case, the combination as claimed does not require the particulars of the subcombination as claimed because 1) the utility of a polynucleotide array does not necessarily depend on the utility

Application/Control Number: 09/774,434

Art Unit: 1634

of each separate polynucleotide in the array, and 2) the polynucleotide array of Group II can be used in a method to identify differential expression of many different genes. The subcombination has separate utility such as the distinct polynucleotides of Group I can be used in recombinant methods to express proteins.

- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.
- 4. Because these inventions are distinct for the reasons given above and the search required for Group I is not required for Group II, restriction for examination purposes as indicated is proper.
- 5. Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).
- 6. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(I).

Application/Control Number: 09/774,434

Page 4

Art Unit: 1634

Any inquiry concerning this communication or earlier communications from the examiner should be directed to examiner Jehanne Souaya whose telephone number is (703)308-6565. The examiner can normally be reached Monday-Friday from 9:00 AM to 6:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Jones, can be reached on (703) 308-1152. The fax phone number for this Group is (703) 305-3014.

Any inquiry of a general nature should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Jehanne Souaya
Patent examiner

Art Unit 1634

10/1/02